(LLY) Eli Lilly - Overview

Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 897.716m USD | Total Return: 31.8% in 12m

Insulin, Diabetes Medications, Weight Loss Drugs, Oncology, Immunology
Total Rating 82
Safety 89
Buy Signal 0.47
Drug Manufacturers - General
Industry Rotation: +6.8
Market Cap: 898B
Avg Turnover: 3.34B
Risk 3d forecast
Volatility35.2%
VaR 5th Pctl5.56%
VaR vs Median-5.14%
Reward TTM
Sharpe Ratio0.80
Rel. Str. IBD60
Rel. Str. Peer Group61.7
Character TTM
Beta0.793
Beta Downside0.596
Hurst Exponent0.513
Drawdowns 3y
Max DD34.48%
CAGR/Max DD0.95
CAGR/Mean DD3.62
EPS (Earnings per Share) EPS (Earnings per Share) of LLY over the last years for every Quarter: "2021-03": 1.87, "2021-06": 1.87, "2021-09": 1.94, "2021-12": 2.49, "2022-03": 2.77, "2022-06": 1.25, "2022-09": 1.98, "2022-12": 2.09, "2023-03": 1.62, "2023-06": 2.11, "2023-09": 0.1, "2023-12": 2.49, "2024-03": 2.58, "2024-06": 3.92, "2024-09": 1.18, "2024-12": 5.32, "2025-03": 3.34, "2025-06": 6.31, "2025-09": 7.02, "2025-12": 7.54, "2026-03": 8.55,
EPS CAGR: 66.99%
EPS Trend: 60.8%
Last SUE: 2.47
Qual. Beats: 1
Revenue Revenue of LLY over the last years for every Quarter: 2021-03: 6805.6, 2021-06: 6740.1, 2021-09: 6772.8, 2021-12: 7999.9, 2022-03: 7810, 2022-06: 6488, 2022-09: 6941.6, 2022-12: 7301.8, 2023-03: 6960, 2023-06: 8312.1, 2023-09: 9498.6, 2023-12: 9353.4, 2024-03: 8768, 2024-06: 11302.8, 2024-09: 11439.1, 2024-12: 13532.8, 2025-03: 12728.5, 2025-06: 15557.7, 2025-09: 17600.8, 2025-12: 19292, 2026-03: 19799,
Rev. CAGR: 34.65%
Rev. Trend: 98.2%
Last SUE: 2.35
Qual. Beats: 4

Warnings

No concerns identified

Tailwinds

Confidence, Garp

Description: LLY Eli Lilly

Eli Lilly and Company is a global pharmaceutical firm headquartered in Indianapolis, specializing in the development and manufacturing of treatments for chronic and complex conditions. Its portfolio is heavily weighted toward cardiometabolic health, oncology, immunology, and neuroscience, with a significant focus on incretin-based therapies for diabetes and obesity management.

The company operates within the high-barrier-to-entry biopharmaceutical sector, where growth is driven by rigorous research and development cycles and patent protection. Its business model relies on large-scale clinical trials and strategic collaborations with global partners like Boehringer Ingelheim and Roche to co-develop and commercialize specialized molecular entities.

For a more detailed breakdown of these product pipelines and clinical milestones, you may wish to consult ValueRay. Eli Lilly maintains a diversified revenue stream by targeting high-prevalence diseases such as Alzheimers and rheumatoid arthritis across major international markets including the United States, Europe, and China.

Headlines to Watch Out For
  • Mounjaro and Zepbound sales growth drives significant GLP-1 market share expansion
  • Manufacturing capacity constraints limit short-term revenue potential for obesity portfolio
  • Medicare pricing negotiations and patent expirations pose long-term margin risks
  • Kisunla commercialization creates new revenue stream in the Alzheimers market
  • Clinical trial success for oral GLP-1 candidates influences future valuation premium
Piotroski VR‑10 (Strict) 7.0
Net Income: 25.27b TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 13.07 > 1.0
NWC/Revenue: 25.19% < 20% (prev 22.84%; Δ 2.35% < -1%)
CFO/TA 0.18 > 3% & CFO 20.48b > Net Income 25.27b
Net Debt (38.09b) to EBITDA (33.13b): 1.15 < 3
Current Ratio: 1.50 > 1.5 & < 3
Outstanding Shares: last quarter (895.9m) vs 12m ago -0.52% < -2%
Gross Margin: 83.51% > 18% (prev 0.82%; Δ 8.27k% > 0.5%)
Asset Turnover: 70.16% > 50% (prev 54.82%; Δ 15.34% > 0%)
Interest Coverage Ratio: 35.68 > 6 (EBITDA TTM 33.13b / Interest Expense TTM 883.6m)
Altman Z'' 4.24
A: 0.16 (Total Current Assets 54.84b - Total Current Liabilities 36.63b) / Total Assets 116.58b
B: 0.25 (Retained Earnings 29.51b / Total Assets 116.58b)
C: 0.31 (EBIT TTM 31.52b / Avg Total Assets 102.98b)
D: 0.32 (Book Value of Equity 27.27b / Total Liabilities 85.38b)
Altman-Z'' Score: 4.24 = AA
Beneish M -2.70
DSRI: 1.03 (Receivables 21.18b/14.00b, Revenue 72.25b/49.00b)
GMI: 0.98 (GM 83.51% / 81.70%)
AQI: 0.91 (AQ_t 0.30 / AQ_t-1 0.33)
SGI: 1.47 (Revenue 72.25b / 49.00b)
TATA: 0.04 (NI 25.27b - CFO 20.48b) / TA 116.58b)
Beneish M-Score: -2.70 (Cap -4..+1) = A
What is the price of LLY shares? As of May 19, 2026, the stock is trading at USD 988.09 with a total of 1,602,915 shares traded.
Over the past week, the price has changed by +2.36%, over one month by +7.60%, over three months by -3.01% and over the past year by +31.78%.
Is LLY a buy, sell or hold? Eli Lilly has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy LLY.
  • StrongBuy: 16
  • Buy: 7
  • Hold: 4
  • Sell: 1
  • StrongSell: 1
What are the forecasts/targets for the LLY price?
Analysts Target Price 1209.1 22.4%
Eli Lilly (LLY) - Fundamental Data Overview as of 16 May 2026
P/E Trailing = 35.7112
P/E Forward = 26.3158
P/S = 12.4253
P/B = 27.1098
P/EG = 1.2799
Revenue TTM = 72.25b USD
EBIT TTM = 31.52b USD
EBITDA TTM = 33.13b USD
Long Term Debt = 39.37b USD (from longTermDebt, last quarter)
Short Term Debt = 4.00b USD (from shortTermDebt, last quarter)
Debt = 43.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 38.09b USD (from netDebt column, last quarter)
Enterprise Value = 935.80b USD (897.72b + Debt 43.37b - CCE 5.28b)
Interest Coverage Ratio = 35.68 (Ebit TTM 31.52b / Interest Expense TTM 883.6m)
EV/FCF = 68.91x (Enterprise Value 935.80b / FCF TTM 13.58b)
FCF Yield = 1.45% (FCF TTM 13.58b / Enterprise Value 935.80b)
FCF Margin = 18.80% (FCF TTM 13.58b / Revenue TTM 72.25b)
Net Margin = 34.98% (Net Income TTM 25.27b / Revenue TTM 72.25b)
Gross Margin = 83.51% ((Revenue TTM 72.25b - Cost of Revenue TTM 11.92b) / Revenue TTM)
Gross Margin QoQ = 81.93% (prev 85.05%)
Tobins Q-Ratio = 8.03 (Enterprise Value 935.80b / Total Assets 116.58b)
Interest Expense / Debt = 0.77% (Interest Expense 332.0m / Debt 43.37b)
Taxrate = 16.43% (1.45b / 8.85b)
NOPAT = 26.34b (EBIT 31.52b * (1 - 16.43%))
Current Ratio = 1.50 (Total Current Assets 54.84b / Total Current Liabilities 36.63b)
Debt / Equity = 1.39 (Debt 43.37b / totalStockholderEquity, last quarter 31.20b)
Debt / EBITDA = 1.15 (Net Debt 38.09b / EBITDA 33.13b)
Debt / FCF = 2.80 (Net Debt 38.09b / FCF TTM 13.58b)
Total Stockholder Equity = 24.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 24.54% (Net Income 25.27b / Total Assets 116.58b)
RoE = 101.3% (Net Income TTM 25.27b / Total Stockholder Equity 24.95b)
RoCE = 49.01% (EBIT 31.52b / Capital Employed (Equity 24.95b + L.T.Debt 39.37b))
RoIC = 39.31% (NOPAT 26.34b / Invested Capital 67.02b)
WACC = 8.40% (E(897.72b)/V(941.09b) * Re(8.77%) + D(43.37b)/V(941.09b) * Rd(0.77%) * (1-Tc(0.16)))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -77.78 | Cagr: -0.40%
[DCF] Terminal Value 68.89% ; FCFF base≈13.58b ; Y1≈8.92b ; Y5≈4.08b
[DCF] Fair Price = 41.96 (EV 75.51b - Net Debt 38.09b = Equity 37.42b / Shares 891.7m; r=8.40% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 60.81 | EPS CAGR: 66.99% | SUE: 2.47 | # QB: 1
Revenue Correlation: 98.24 | Revenue CAGR: 34.65% | SUE: 2.35 | # QB: 4
EPS current Quarter (2026-06-30): EPS=8.81 | Chg30d=+7.92% | Revisions=+73% | Analysts=20
EPS next Quarter (2026-09-30): EPS=9.40 | Chg30d=+2.80% | Revisions=+43% | Analysts=19
EPS current Year (2026-12-31): EPS=36.07 | Chg30d=+4.22% | Revisions=+67% | GrowthEPS=+49.0% | GrowthRev=+30.6%
EPS next Year (2027-12-31): EPS=44.28 | Chg30d=+5.30% | Revisions=+70% | GrowthEPS=+22.8% | GrowthRev=+14.6%
[Analyst] Revisions Ratio: +73%